TRAIL promotes hepatocellular carcinoma apoptosis and inhibits proliferation and migration via interacting with IER3

Table 2 Spearman analysis of correlation between TUG1 and clinicopathological

Variables	IER3 expression level
Variables	Spearman correlation	p value
Age (years, < 50 vs. ≥ 50)	− 0.129	0.224
Gender (male/female)	0.039	0.712
HBsAg (positive/negative)	0.179	0.094
HBcAb (positive/negative)	0.151	0.163
HCV (positive/negative)	0.099	0.359
Liver cirrhosis (yes/no)	− 0.086	0.425
Total bilirubin (mmol/L, < 21 vs. ≥ 21)	0.09	0.403
ALT (U/L, < 60 vs. ≥ 60)	− 0.179	0.094
GGT (U/L, < 40 vs. ≥ 40)	− 0.23	0.03
Cirrhotic nodules (single/multiple)	0.032	0.768
Vascular invasion (yes/no)	− 0.14	0.219
Tumor number (single/multiple)	0.001	0.994
Tumor size (cm, < 5 vs. ≥ 5)	− 0.414	< 0.001
Recrudescence (yes/no)	− 0.21	0.047
AJCC TNM stage (I + II vs III + IV)	− 0.079	0.461

Italics numbers indicate significant differences (P < 0.05)
HCC hepatocellular carcinoma, HBsAg hepatitis B surface antigen, HBcAb hepatitis B core antigen, HCV hepatitis C virus, ALT alanine transaminase, GGT Gamma-Glutamyltransferase, AFP α-fetoprotein, AJCC the American Joint Committee on Cancer, TNM tumor-node-metastasis

ISSN: 1475-2867